Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Lewy Body Dementia Pipeline Drug Analysis Report Overview
Lewy body dementia (LBD) is a common type of dementia that happens when clumps of proteins called Lewy bodies build up in the brain. They damage parts of the brain that affect cognition, behavior, movement, and sleep. Lewy body intracellular inclusions result from the aggregation of misfolded α-synuclein. There will be more than 1.1 million diagnosed prevalent cases of LBD in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for LBD. LBD is a progressive condition. There is no cure, but medications and therapies can help manage symptoms. In people over the age of 65, LBD is one of the most common causes of dementia. Men are more likely to develop LBD than women. A family history of LBD and Parkinson’s disease (PD) also increases the risk of developing the disease.
The LBD marketed and pipeline drugs market research offers a competitive landscape combining data from the pharma intelligence center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. This report provides a data-driven overview of the current and future competitive landscape in LBD therapeutics.
Key Mechanisms of Action (Marketed Drugs) | Enzyme Inhibitors and Ion Channel Blockers |
Key Mechanisms of Action (Pipeline Drugs) | Enzyme Inhibitor, Protein and Peptide Inhibitor, Receptor Agonist, Receptor Antagonist, Receptor Inhibitor, Enzyme Replacement, Protein and Peptide Activator, Biological Factor Activator, and Enzyme Activator |
Key Routes of Administration (Pipeline Drugs) | Oral, Injection, and Inhalational |
Key Molecule Types (Pipeline Drugs) | Small Molecule, and Biologics |
Top Sponsors (Marketed and Pipeline Drugs) | Sio Gene Therapies Inc, Eisai Co Ltd, Georgetown University, Sumitomo Pharma Co Ltd, Cognition Therapeutics Inc, Rodin Therapeutics Inc, MD Stem Cells, Athira Pharma Inc, Acadia Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, and EIP Pharma LLC among others. |
Lewy Body Dementia Marketed Drugs Segmentation by Mechanism of Action
The key mechanisms of action for LBD marketed drugs are enzyme inhibitors and ion channel blockers. The enzyme inhibitors accounted for most marketed drugs for LBD.
Lewy Body Dementia Marketed Drugs Analysis by MoA, 2023 (%)
For more MoA insights into Lewy Body Dementia marketed drugs, download a free report sample
Lewy Body Dementia Pipeline Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for LBD pipeline drugs are enzyme inhibitor, protein and peptide inhibitor, receptor agonist, receptor antagonist, receptor inhibitor, enzyme replacement, protein and peptide activator, biological factor activator, and enzyme activator. Most of the LBD pipeline drugs are enzyme inhibitor.
Lewy Body Dementia Pipeline Drugs Analysis by MoA, 2023 (%)
For more MoA insights into the LBD pipeline drugs market, download a free report sample
Lewy Body Dementia Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for Lewy Body Dementia pipeline drugs are oral, injection, and inhalational. The pipeline drugs for LBD are mostly by oral, followed by injection and inhalational.
Lewy Body Dementia Pipeline Drugs Analysis by RoA, 2023 (%)
For more RoA insights into the LBD pipeline drugs market, download a free report sample
Lewy Body Dementia Pipeline Drugs Segmentation by Molecule Type
Most of the pipeline drugs for LBD are small molecules, followed by biologics.
Lewy Body Dementia Pipeline Drugs Analysis by Molecule Types, 2023 (%)
For more molecule type insights into the LBD pipeline drugs market, download a free report sample
Top Sponsors in the LBD Marketed and Pipeline Drugs Market
Some of the top sponsors in the LBD marketed and pipeline drugs market are Sio Gene Therapies Inc, Eisai Co Ltd, Georgetown University, Sumitomo Pharma Co Ltd, Cognition Therapeutics Inc, Rodin Therapeutics Inc, MD Stem Cells, Athira Pharma Inc, Acadia Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, and EIP Pharma LLC among others. Sio Gene Therapies has sponsored the highest number of clinical trials (eight) of all the trials initiated in LBD over the past 10 years, followed by Eisai (four).
Segments Covered in the Report
LBD Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Ion Channel Blockers
- Enzyme Inhibitor
LBD Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Inhibitor
- Protein And Peptide Inhibitor
- Receptor Agonist
- Receptor Antagonist
- Receptor Inhibitor
- Enzyme Replacement
- Protein and Peptide Activator
- Biological Factor Activator
- Enzyme Activator
LBD Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Oral
- Injection
- Inhalational
LBD Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecule
- Biologic
Scope
GlobalData’s Lewy Body Dementia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the AC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the main mechanism of action for LBD marketed drugs?
The key mechanisms of action for LBD marketed drugs are enzyme inhibitors.
-
What is the main mechanism of action for LBD pipeline drugs?
The key mechanism of action for LBD pipeline drugs are enzyme inhibitors.
-
What is the key route of administration for LBD pipeline drugs?
Most of the LBD pipeline drugs adopt the oral route of administration.
-
What is the main molecule type for LBD pipeline drugs?
Small molecules are mostly used molecule types for LBD pipeline drugs.
-
Who are the top sponsors for LBD marketed and pipeline drugs market?
Some of the top sponsors in the LBD marketed and pipeline drugs market are Sio Gene Therapies Inc, Eisai Co Ltd, Georgetown University, Sumitomo Pharma Co Ltd, Cognition Therapeutics Inc, Rodin Therapeutics Inc, MD Stem Cells, Athira Pharma Inc, Acadia Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, and EIP Pharma LLC among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.